Statement: in the primary clinical trial, fulvestrant is given intramuscularly and everolimus is administered orally to the participants
Primary_evidence: INTERVENTION 1:    Fulvestrant + Everolimus   Fulvestrant + Everolimus   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.